Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1491)	10/18/2006 3:14:52 PM
From: Icebrg	Read Replies (1) \| Respond to of 2240

I have no idea, really. Genmab has more late-stage projects and their targets are validated. If their antibodies are "better" than the current generation is not known. One should also keep in mind that Genmab is traded on a relative small equity market with very few other companies in the sector. Most investors have not been exposed to simular companies and their investment in Genmab might be their first exposure to the biotech sector. Under such circumstances highs tend to be too high and lows too low. Erik